During the last session, Ocular Therapeutix Inc (NASDAQ:OCUL)’s traded shares were 2.84 million, with the beta value of the company hitting 1.56. At the end of the trading day, the stock’s price was $7.15, reflecting an intraday gain of 10.00% or $0.65. The 52-week high for the OCUL share is $11.77, that puts it down -64.62 from that peak though still a striking 43.22% gain since the share price plummeted to a 52-week low of $4.06. The company’s market capitalization is $1.14B, and the average trade volume was 952.57K shares over the past three months.
Ocular Therapeutix Inc (OCUL) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.10. OCUL has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.28.
Ocular Therapeutix Inc (NASDAQ:OCUL) trade information
Ocular Therapeutix Inc (OCUL) registered a 10.00% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 10.00% in intraday trading to $7.15, hitting a weekly high. The stock’s 5-day price performance is 3.03%, and it has moved by -5.30% in 30 days. Based on these gigs, the overall price performance for the year is -33.49%.
The consensus price target of analysts on Wall Street is $16, which implies an increase of 55.31% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $14 and $24 respectively. As a result, OCUL is trading at a discount of -235.66% off the target high and -95.8% off the low.
Ocular Therapeutix Inc (OCUL) estimates and forecasts
In the rating firms’ projections, revenue will increase 13.00% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 17.22M as predicted by 7 analyst(s). Meanwhile, a consensus of 7 analyst(s) estimates revenue growth to 17.96M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 14.77M and 16.44M respectively. In this case, analysts expect current quarter sales to grow by 16.58% and then jump by 9.27% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 8.51%. While earnings are projected to return 0.49% in 2025, the next five years will return 6.65% per annum.
OCUL Dividends
Ocular Therapeutix Inc is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 11.52 million shares, is of BLACKROCK INC.’s that is approximately 8.7261% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $78.8 million.
Also, the Mutual Funds coming in first place with the largest holdings of Ocular Therapeutix Inc (OCUL) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 4.64 shares. This amounts to just over 2.95 percent of the company’s overall shares, with a $33.14 million market value. The same data shows that the other fund manager holds slightly less at 4.21, or about 2.68% of the stock, which is worth about $30.13 million.
